Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

Authors: Guilhot, François ^{1, ∗}, Hehlmann, Rüdiger ^{2, 3}

Source: In Blood 27 February 2025 145(9):910-920

Rapport 24-11. Offre de soins en cancérologie adulte

Alternate Title: Adult cancer care (English)

Authors: Villet, Richard ^⁎, Lartigau, Éric, Blay, Jean Yves, Guilhot, François, Rouëssé, Jacques

Source: In Bulletin de l'Académie Nationale de Médecine January 2025 209(1):15-34

Rapport 23-22. Médicaments anti cancéreux onéreux : Disponibilité et soutenabilité économique

Alternate Title: Expensive cancer drugs: Availability and economic sustainability (English)

Authors: Guilhot, François, Rouësse, Jacques, Bouvenot, Gilles, Dreno, Brigitte, Facon, Thierry, Gorin, Norbert Claude, Juillet, Yves, Blay, Jean-Yves, Le Coz, Pierre, Villet, Richard

Source: In Bulletin de l'Académie Nationale de Médecine January 2024 208(1):9-24

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Authors: Guilhot, Francois, Rigal-Huguet, Françoise, Guilhot, Joëlle, Guerci-Bresler, Agnès-Paule, Maloisel, Frédéric, Rea, Delphine, Coiteux, Valérie, Gardembas, Martine, Berthou, Christian, Vekhoff, Anne, Jourdan, Eric, Berger, Marc, Fouillard, Loïc, Alexis, Magda, Legros, Laurence, Rousselot, Philippe, Delmer, Alain, Lenain, Pascal, Escoffre Barbe, Martine, Gyan, Emmanuel, Bulabois, Claude-Eric, Dubruille, Viviane, Joly, Bertrand, Pollet, Bertrand, Cony-Makhoul, Pascale, Johnson-Ansah, Hyacinthe, Mercier, Melanie, Caillot, Denis, Charbonnier, Aude, Kiladjian, Jean-Jacques, Chapiro, Jacques, Penot, Amélie, Dorvaux, Véronique, Vaida, Iona, Santagostino, Alberto, Roy, Lydia, Zerazhi, Hacene, Deconinck, Eric, Maisonneuve, Herve, Plantier, Isabelle, Lebon, Delphine, Arkam, Yazid, Cambier, Nathalie, Ghomari, Kamel, Miclea, Jean-Michel, Glaisner, Sylvie, Cayuela, Jean-Michel, Chomel, Jean-Claude, Muller, Marc, Lhermitte, Ludovic, Delord, Marc, Preudhomme, Claude, Etienne, Gabriel, Mahon, François-Xavier, Nicolini, Franck- Emmanuel

Source: Leukemia. 35(8):2332-2345

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193006814.0x000001&indx=1&recIds=ETOCvdc_100193006814.0x000001

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Authors: Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., Kantarjian, Hagop M.

Source: In Blood 26 July 2018 132(4):393-404

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Authors: Ossenkoppele, Gert, Pagoni, Maria N., Söderlund, Stina, Escoffre-Barbe, Martine, Etienne, Gabriel, Dengler, Jolanta, Huguet, Francoise, von Bubnoff, Nikolas, Klamova, Hana, Faber, Edgar, Guilhot, Francois, Lotfi, Kourosh, Rea, Delphine, Brümmendorf, Tim H., de Greef, Gorgine E., Stenke, Leif, Nicolini, Franck E., Legros, Laurence, Burchert, Andreas, Voglova, Jaroslava, Charbonnier, Aude, Gyan, Emmanuel, Kunzmann, Volker, Westerweel, Peter E., Saussele, Susanne, Richter, Johan, Guilhot, Joelle, Gruber, Franz X, Hjorth-Hansen, Henrik, Almeida, Antonio, Janssen, Jeroen J W M, Mayer, Jiri, Koskenvesa, Perttu, Panayiotidis, Panayiotis, Olsson-Strömberg, Ulla, Martinez-Lopez, Joaquin, Rousselot, Philippe, Vestergaard, Hanne, Ehrencrona, Hans, Kairisto, Veli, Machová Poláková, Katerina, Müller, Martin C, Mustjoki, Satu, Berger, Marc G, Fabarius, Alice, Hofmann, Wolf-Karsten, Hochhaus, Andreas, Pfirrmann, Markus, Mahon, Francois-Xavier

Source: In The Lancet Oncology June 2018 19(6):747-757

Help for Ukrainian Hematology Patients (HUP): A Global Initiative Supporting Hematopoietic Stem Cell Transplantation (HSCT) Programs in a Time of Conflict

Authors: Korenkova, Irina, Bitan, Menachem, Klymenko, Sergiy, Lysytsia, Oleksandr, Zaucha, Jan, Mytilineos, Joannis, Haferlach, Torsten, Hochaus, Andreas, Heyman, Mats, Guilhot, Francois, Bolanos, Natascha, Kuts, Roman, Greinix, HIldegard, Koh, Mickey B C, Landgraf, Susan, Hehlmann, Rudiger, Aljurf, Mahmoud, Sureda, Anna, Rondelli, Damiano, Niederwieser, Dietger

Source: Transplantation and Cellular Therapy. 29(S):S301-S302

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100180673065.0x000001&indx=1&recIds=ETOCvdc_100180673065.0x000001

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Authors: Rea, Delphine, Nicolini, Franck E., Tulliez, Michel, Guilhot, François, Guilhot, Joelle, Guerci-Bresler, Agnès, Gardembas, Martine, Coiteux, Valérie, Guillerm, Gaelle, Legros, Laurence, Etienne, Gabriel, Pignon, Jean-Michel, Villemagne, Bruno, Escoffre-Barbe, Martine, Ianotto, Jean-Christophe, Charbonnier, Aude, Johnson-Ansah, Hyacinthe, Noel, Marie-Pierre, Rousselot, Philippe, Mahon, François-Xavier

Source: In Blood 16 February 2017 129(7):846-854

Résultats du traitement de la leucémie myéloïde chronique par inhibiteurs de tyrosine kinase seuls ou associés à l’interféron

Alternate Title: Results of the treatment of chronic myeloid leukemia by tyrosine kinase inhibitors alone or in combination with interferon (English)

Authors: Guilhot, François

Source: In Bulletin de l'Académie Nationale de Médecine January-March 2017 201(1-3):157-166

Beyond tyrosine kinase inhibitors: Combinations and other agents

Authors: Cayssials, Emilie, Guilhot, Francois

Source: In Best Practice & Research Clinical Haematology September 2016 29(3):271-283

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia

Authors: Khoury, Hanna J., Goldberg, Stuart L., Mauro, Michael J., Stone, Richard M., Deininger, Michael W., Bradley-Garelik, M. Brigid, Mohamed, Hesham, Guilhot, François

Source: In Clinical Lymphoma Myeloma and Leukemia June 2016 16(6):341-349

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Authors: Lipton, Jeffrey H, Chuah, Charles, Guerci-Bresler, Agnès, Rosti, Gianantonio, Simpson, David, Assouline, Sarit, Etienne, Gabriel, Nicolini, Franck E, le Coutre, Philipp, Clark, Richard E, Stenke, Leif, Andorsky, David, Oehler, Vivian, Lustgarten, Stephanie, Rivera, Victor M, Clackson, Timothy, Haluska, Frank G, Baccarani, Michele, Cortes, Jorge E, Guilhot, François, Hochhaus, Andreas, Hughes, Timothy, Kantarjian, Hagop M, Shah, Neil P, Talpaz, Moshe, Deininger, Michael W

Source: In The Lancet Oncology May 2016 17(5):612-621

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Authors: Deininger, Michael W. ^*, Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., Branford, Susan

Source: In Blood 11 February 2016 127(6):703-712

The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia

Authors: Dkhissi, Fatima, Aggoune, Djamel, Pontis, Julien, Sorel, Nathalie, Piccirilli, Nathalie, LeCorf, Amélie, Guilhot, François, Chomel, Jean-Claude, Ait-Si-Ali, Slimane, Turhan, Ali G.

Source: In Experimental Hematology September 2015 43(9):775-780

Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Authors: Beaussant, Yvan, Daguindau, Etienne, Pugin, Aurore, Mohty, Mohamad, Avet-Loiseau, Hervé, Roos-Weil, Damien, Michallet, Mauricette, Chevalier, Patrice, Raus, Nicole, El-Cheikh, Jean, Tabrizi, Reza, Huyn, Anne, Buzyn, Agnès, Socié, Gérard, Vincent, Laure, Guilhot, François, Yakoub-Agha, Ibrahim, Lenain, Pascal, François, Sylvie, Beckerich, Florence, Lioure, Bruno, Bulabois, Claude-Eric, Deconinck, Eric

Source: In Biology of Blood and Marrow Transplantation August 2015 21(8):1452-1459

Imatinib treatment and Aβ42 in humans

Authors: Olsson, Bob, Legros, Laurence, Guilhot, François, Strömberg, Kia, Smith, James, Livesey, Frederick J., Wilson, David H., Zetterberg, Henrik, Blennow, Kaj

Source: In Alzheimer's & Dementia: The Journal of the Alzheimer's Association October 2014 10(5) Supplement:S374-S380

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

Authors: Shah, Neil P., Guilhot, François, Cortes, Jorge E., Schiffer, Charles A., le Coutre, Philipp, Brümmendorf, Tim H., Kantarjian, Hagop M., Hochhaus, Andreas, Rousselot, Philippe, Mohamed, Hesham, Healey, Diane, Cunningham, Michael, Saglio, Giuseppe

Source: In Blood 10 April 2014 123(15):2317-2324

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24

Authors: Efficace, Fabio, Baccarani, Michele, Breccia, Massimo, Saussele, Susanne, Abel, Gregory, Caocci, Giovanni, Guilhot, Francois, Cocks, Kim, Naeem, Adel, Sprangers, Mirjam, Oerlemans, Simone, Chie, Weichu, Castagnetti, Fausto, Bombaci, Felice, Sharf, Giora, Cardoni, Annarita, Noens, Lucien, Pallua, Stephan, Salvucci, Marzia, Nicolatou-Galitis, Ourania, Rosti, Gianantonio, Mandelli, Franco

Source: Quality of Life Research, 2014 Apr 01. 23(3), 825-836.

Access URL: https://www.jstor.org/stable/24726381

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

Authors: Hughes, Timothy P., Saglio, Giuseppe, Kantarjian, Hagop M., Guilhot, François, Niederwieser, Dietger, Rosti, Gianantonio, Nakaseko, Chiaki, De Souza, Carmino Antonio, Kalaycio, Matt E., Meier, Stephan, Fan, Xiaolin, Menssen, Hans D., Larson, Richard A., Hochhaus, Andreas

Source: In Blood 27 February 2014 123(9):1353-1360

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Authors: Baccarani, Michele ^*, Deininger, Michael W., Rosti, Gianantonio, Hochhaus, Andreas, Soverini, Simona, Apperley, Jane F., Cervantes, Francisco, Clark, Richard E., Cortes, Jorge E., Guilhot, François, Hjorth-Hansen, Henrik, Hughes, Timothy P., Kantarjian, Hagop M., Kim, Dong-Wook, Larson, Richard A., Lipton, Jeffrey H., Mahon, François-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Pane, Fabrizio, Radich, Jerald P., Rousselot, Philippe, Saglio, Giuseppe, Saußele, Susanne, Schiffer, Charles, Silver, Richard, Simonsson, Bengt, Steegmann, Juan-Luis, Goldman, John M., Hehlmann, Rüdiger

Source: In Blood 8 August 2013 122(6):872-884